[Use of creatine phosphate in treatment of cardiocerebral syndrome associated with acute myocardial infarct in the aged].
BACKGROUND
The objective of the investigation was to compare possibilities how to influence the general neuropsychic symptomatology described as cardiocerebral syndrome during the first three days of an acute myocardial infarction (AIM) in old age by means of creatine phosphate (CP).


RESULTS
The investigation which extended over 8 months comprised 50 subjects admitted to the coronary unit (CU) because of AIM symptomatology, age 65-93 years (75.1 +/- 5.6 years). Twenty-five subjects were given, using a uniform protocol, during the first three days at the CU, 18 g CP (Neoton, Schiapparelli) by the i.v. rut. The control group of 25 subjects (randomized) with AIM of comparable parameters (age, sex, location and course of IM) were not given CP. Evaluation of the dynamics of mental deterioration by means of a test of cognitive functions (MMS) during the first three days after IM by means of simple regression analysis, comparing the two groups, revealed a favourable effect of CP on mental functions as compared with the control group (p = 0.05). In the CP treated group there was, as compared with the control group, on the 1st and 2nd day a lower incidence of stenocardias (statistically not significant; p = NS), ventricular dysrhythmias (p = NS) and cardiac failure (p = NS).


CONCLUSIONS
Administration of creatine phosphate did not produce any undesirable side effects. Objective evidence was provided of the favourable effect of CP on mental deterioration in cardiocerebral syndrome in AIM in old age.
Weber
P
P
1. interní klinika Fakultní nemocnice, Brno, Bohunice.
Vlasicová
Y
Y
Lábrová
R
R
Semrád
B
B
D000368:Aged; D000369:Aged, 80 and over; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000150:complications*; D010725:Phosphocreatine / Q000627:therapeutic use*
D010725:Phosphocreatine
Prínos uzití kreatinfosfátu v terapii kardiocerebrálního syndromu u akutního infarktu myokardu ve stárí.